Marjolein A. Van Der Klift

Breda, NB, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: December 08, 2025

Cost-Effectiveness of Venetoclax-Based Treatment in Treatment-Naïve Fit Patients With CLL Without TP53 Aberrations.

Cost-Effectiveness of Venetoclax-Based Treatment in Treatment-Naïve Fit Patients With CLL Without TP53 Aberrations.

Journal: European journal of haematology

Published: December 05, 2025

Cost-Effectiveness of Venetoclax-Based Treatment in Treatment-Naïve Fit Patients With CLL Without TP53 Aberrations.

Cost-Effectiveness of Venetoclax-Based Treatment in Treatment-Naïve Fit Patients With CLL Without TP53 Aberrations.

Journal: European journal of haematology

Published: December 05, 2025

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Journal: Nature medicine

Published: June 27, 2025

Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial.

Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology

Published: June 06, 2025

Impact of comorbidity on health-related quality of life in newly diagnosed patients with lymphoma or multiple myeloma: results from the PROFILES-registry.

Impact of comorbidity on health-related quality of life in newly diagnosed patients with lymphoma or multiple myeloma: results from the PROFILES-registry.

Journal: Annals of hematology

Published: July 10, 2024

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: May 10, 2023

High Hospital-related Costs at the End-of-life in Patients With Multiple Myeloma: A Single-center Study.

High Hospital-related Costs at the End-of-life in Patients With Multiple Myeloma: A Single-center Study.

Journal: HemaSphere

Published: March 23, 2023

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.

Journal: Blood

Published: February 22, 2023

Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study.

Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study.

Journal: The patient

Published: January 17, 2023

Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.

Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.

Journal: Leukemia & lymphoma

Published: June 23, 2022

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands.

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands.

Journal: Blood cancer journal

Published: November 30, 2021

Showing 1-12 of 24

Last Updated: 09/26/2026